Nodal distribution and its significance in FIGO stage IIIc endometrial cancer.

OBJECTIVE The aim of this study was to describe the distribution of nodal disease in FIGO Stage IIIc endometrial cancer (EC) and to evaluate whether nodal distribution is related to recurrence and survival. METHODS Charts from EC patients with FIGO Stage IIIc disease from 1989 to 1998 were abstracted for clinicopathologic data, pelvic (PLN) and para-aortic (PALN) nodal involvement, number of positive/removed nodes, and extranodal disease spread. Patterns of nodal distribution were evaluated for site of first recurrence and survival. Associations between variables were tested by chi(2) and Wilcoxon rank sums. Survival analyses were performed by the Kaplan-Meier method. RESULTS Of 607 EC patients evaluated, 47 were identified with FIGO Stage IIIc disease. All 47 patients underwent hysterectomy and PLN sampling, and 42/47 had PALN sampling. The median number of PLN removed was 16 (range 2-35), and the median number of PALN was 7 (0-18). Stage IIIc disease was defined by positive PLN alone in 43%, positive PLN and PALN in 40%, and positive PALN alone in 17%. Positive peritoneal cytology and/or adnexal metastasis were present in 12 patients. Only 1/12 of these patients had isolated positive PLN whereas 11/12 had positive PALN (P = 0.007). An increasing number of positive PLN was associated with PALN metastasis (P = 0.0001), and of the 10 patients with bilateral PLN involvement, 9/10 also had positive PALN (P = 0.001). Sites of first recurrence were similar regardless of whether PALN were positive. At a median follow-up of 37 months, the 3-year survival estimate was 70% for patients with positive PALN versus 87% for those with isolated PLN disease (P = 0.22). For all patients neither the total number of positive PLN nor the total number of PLN or PALN removed was associated with survival. CONCLUSIONS PALN involvement is common in patients with FIGO Stage IIIc endometrial cancer, suggesting that PLN sampling alone may result in underdiagnosis of disease. Patients with positive PALN had more extensive disease, but survival and patterns of failure were not significantly different from those with disease confined to PLN, suggesting that lymph node dissection may have a therapeutic role.

[1]  R. Mannel,et al.  Analysis of FIGO Stage IIIc endometrial cancer patients. , 2001, Gynecologic oncology.

[2]  P. Rose Type II radical hysterectomy: evaluating its role in cervical cancer. , 2001, Gynecologic oncology.

[3]  G. Sutton,et al.  FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes: analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. , 1999, Gynecologic oncology.

[4]  N. Sakuragi,et al.  A clinical and pathologic study on para‐aortic lymph node metastasis in endometrial carcinoma , 1997, Journal of surgical oncology.

[5]  D. Gershenson,et al.  Staging laparotomy for endometrial carcinoma: assessment of retroperitoneal lymph nodes. , 1995, Gynecologic oncology.

[6]  R. Mannel,et al.  Incidence and location of para-aortic lymph node metastases in gynecologic malignancies. , 1995, Journal of the American College of Surgeons.

[7]  E. Partridge,et al.  Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. , 1995, Gynecologic oncology.

[8]  B. Corn,et al.  Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence , 1993, Cancer.

[9]  D. Schultz,et al.  Endometrial cancer with para-aortic adenopathy: patterns of failure and opportunities for cure. , 1992, International journal of radiation oncology, biology, physics.

[10]  R. Kurman,et al.  Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A gynecologic oncology group study , 1991 .

[11]  B. Bundy,et al.  Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group study , 1987, Cancer.

[12]  P. Grigsby,et al.  Results of therapy, analysis of failures, and prognostic factors for clinical and pathologic stage III adenocarcinoma of the endometrium. , 1987, Gynecologic oncology.

[13]  L. Gerig,et al.  Stage III carcinoma of the endometrium: A review of 41 cases , 1987 .